



Vaccines against Hepatitis Viruses

Guest Editor:

Dr. Dirk Wohlleber

Institute of Molecular
Immunology, Technical
University of Munich, 80333
Munich, Germany

Deadline for manuscript
submissions:

closed (31 March 2021)

Message from the Guest Editor

Dear Colleagues,

Hepatitis viruses cause substantial morbidity and mortality worldwide. Immune therapy in the form of vaccination is considered the best option to prevent infection and the sequelae of chronic viral hepatitis, i.e., liver cirrhosis and liver cell cancer. Despite a prophylactic vaccination against Hepatitis B that efficiently protects against infection, numbers of patients with chronic hepatitis B did not decline over the last 10 years and more than 800,000 patients die from the consequences of chronic hepatitis every year. A therapeutic vaccination is therefore needed because no curative anti-viral treatment is available so far.

This issue focuses on the current research towards immunity against viral infections of the liver. Understanding the interaction of local immune cells in the liver with hepatocytes and non-parenchymal liver cells may be crucial in developing translational approaches to establish treatment strategies to overcome chronic viral hepatitis.

Dr. Dirk Wohlleber
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com